Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
Open Access
- 18 November 2022
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 29 (11) , 8937-8954
Abstract
Background. Chemoimmunotherapy has become the first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC). Still, reliable biomarkers to identify patients who could benefit from this combined therapy remain uncertain. This study focused on elucidating the predictive significance of the monocyte-to-lymphocyte ratio (MLR) and establishing the prognostic nomogram for unresectable ESCC treated with chemoimmunotherapy. Methods. Data of clinical features, peripheral blood parameters, and treatment records were collected in unresectable ESCC patients who received PD-1/PD-L1 inhibitors plus chemotherapy as the first-line treatment from September 2017 to August 2021. The nomogram based on MLR and clinical parameters for predicting the overall survival (OS) was developed and validated. Results. Out of 81 patients enrolled, patients with a lower MLR had significantly longer progression-free survival (PFS) and OS than patients with a higher pretreatment MLR (p = 0.0067; p = 0.00069). The OS nomogram integrating MLR, performance status (PS) score, and body mass index (BMI) achieved a C-index of 0.770 (95%CI 0.645–0.896). The area under the ROC curve (AUC) value of the nomogram predicting 12-, 18-, and 24-month OS rates were 0.855, 0.792, and 0.744, respectively, which were higher than the clinical TNM staging system or the MLR. Stratified by the nomogram-generated scores, three risk groups (low, moderate, and high) in survival curves manifested a distinct difference (p < 0.0001). Conclusion. MLR emerged as an independent predictive factor for PFS and OS in treatment-naive unresectable ESCC patients treated with chemoimmunotherapy. The constructed nomogram of MLR and clinical parameters was a reliable model for prognostic estimation.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LQ19H160042)
This publication has 56 references indexed in Scilit:
- Tumour-associated macrophages as treatment targets in oncologyNature Reviews Clinical Oncology, 2017
- Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor ImmunityCell Metabolism, 2016
- PD-L1 Testing in CancerJAMA Oncology, 2016
- Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysisCancer Treatment Reviews, 2015
- Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specifiedAnnals of Hematology, 2015
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 TherapyClinical Cancer Research, 2014
- Tumor-Associated Macrophages as Major Players in the Tumor MicroenvironmentCancers, 2014
- Targeting interleukin-6 in inflammatory autoimmune diseases and cancersPharmacology & Therapeutics, 2014
- Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganismsNature Reviews Cancer, 2013
- The immune contexture in human tumours: impact on clinical outcomeNature Reviews Cancer, 2012